Compare Garmin Ltd. (GRMN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Novartis AG — how do they compare? Garmin Ltd. trades at $248.05 (market cap $46.62B), while Novartis AG trades at $152.31 (market cap $287.66B). The key difference: Novartis AG is far larger — about 6.2× Garmin Ltd.'s market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| GRMN | NVS | |
|---|---|---|
Market Cap | $46.62B | $287.66B |
Sector | Technology | Health |
52-Week High | $267.52 | $168.62 |
52-Week Low | $187.10 | $113.50 |
Enterprise Value | $44.09B | $327.68B |
Dividend Yield | 1.74% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $241.39, down 0.91% on the day, with a bullish technical signal supported by moving averages and a neutral RSI near 52. The stock shows strong fundamentals with 2025 revenue of $7.25B, net income margin of 23.26%, and consistent earnings beats in recent quarters. Recent product launches in aviation and marine electronics highlight innovation, while cash flow remains positive at $199.21M in 2025.
GRMN presents a solid investment case with robust profitability and growth, though valuation ratios like a P/E of 26.98 suggest premium pricing. Risks include competitive pressures and market volatility, but analyst consensus targets $281.50, indicating ~17% upside. The outlook is positive if earnings momentum continues, supported by dividend stability and institutional confidence.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
